Posted 15 March, 2024

Better Therapeutics, Inc. appointed Craig R. Jalbert as new CEO

Nasdaq:BTTX appointed new Chief Executive Officer Craig R. Jalbert in a 8-K filed on 15 March, 2024.

  On March 14, 2024, the Board appointed Craig R. Jalbert, age 61, as the Company's CEO, President, Treasurer, Secretary, and sole member of the Board.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Better Therapeutics, Inc.
Health Care/Life Sciences • Biotechnology
Better Therapeutics, Inc. operates as a digital therapeutics company, which engages in developing a novel form of cognitive behavioral therapy to address the root causes of cardio metabolic diseases. It offers software-based solutions for type 2 diabetes, heart disease and other conditions. The company was founded by Kevin J. Appelbaum and David P. Perry in April 2015 and is headquartered in San Francisco, CA.
Market Cap
View Company Details
Relevant filing section
Item 5.02. 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 

Resignation of Directors 

On March 14, 2024, Frank Karbe, David Perry, Andrew Armanino, Geoffrey Parker, Dr. Elder Granger, Dr. Risa Lavizzo-Mourey and Dr. Richard Carmona each notified the Company of their respective resignations as members of the Company's board of directors (the "Board") and all committees thereof. None of these resignations resulted from any disagreement with the Company on any matter relating to the Company's operations, policies or practices. 

Termination of Officers 

On March 14, 2024, Dr. Mark Berman and Kristyn Wynholds were each notified by the Company of termination of their positions as Chief Medical Officer and Chief Product Officer, respectively. On March 14, 2024, Frank Karbe resigned from his position as CEO, President, Treasurer and Secretary. 

Election of Director and Officer 

On March 14, 2024, the Board appointed Craig R. Jalbert, age 61, as the Company's CEO, President, Treasurer, Secretary, and sole member of the Board. Mr. Jalbert will also serve as the Company's principal executive officer, and as its principal financial officer and principal accounting officer. Mr. Jalbert's term as director shall expire upon the election and qualification of his successor. Mr. Jalbert has not been appointed to any committee of the Board and as of the date hereof is not expected to be appointed to any committee of the Board. 

Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of officer and director for numerous firms in their wind-down phases. 

In connection with his appointment, Mr. Jalbert will be compensated in the amount of $33,333 per year. There is no arrangement or understanding pursuant to which Mr. Jalbert was appointed to the Board. There are no family relationships between Mr. Jalbert and any director or executive officer of the Company, and Mr. Jalbert has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.